Clinical Nutrition

Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial



The population of the obese is increasing worldwide. Prevention and improvement of obesity are indispensable for decreasing the risk of metabolic disorders. We have recently shown that obesity and fatty liver are reduced by a plant-derived lactic acid bacterium, Pediococcus pentosaceus LP28 (LP28), in high-fat diet-induced obese mice. The aim of the present clinical study is to prove that LP28 is effective for reducing body fat and body weight, as shown in the experiment using mice.


The clinical trial was carried out as a double-blind, randomized, placebo-controlled study comprising 62 subjects (20–70 years of age, BMI 25–30 kg/m2). These subjects were randomly assigned to three groups that received living LP28, heat-killed LP28 or a placebo powder, administered orally once a day for 12 weeks.


Heat-killed LP28 reduced BMI (0.45 kg/m2, 95% CI (0.04, 0.86), P=0.035), body fat percentage (1.11%, (0.39, 1.82), P=0.002), body fat mass (1.17 kg (0.43, 1.92), P=0.004) and waist circumference (2.84 cm (0.74, 4.93), P=0.009) when compared with a placebo group. Fasting plasma glucose, HbA1c, fasting insulin, HOMA-IR and serum lipids levels did not change by either living LP28 or heat-killed LP28 intake.


Heat-killed LP28 displays an antiobesity effect that reduces BMI, body fat and waist circumference, suggesting that the plant-derived lactic acid bacterium LP28 would be a promising preventive of metabolic syndrome.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ et alfor the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557–567.

    Article  Google Scholar 

  2. 2

    Kosaka K, Noda M, Kuzuya T . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152–162.

    Article  Google Scholar 

  3. 3

    Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S et al. Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2013; 56: 284–293.

    Article  Google Scholar 

  4. 4

    Medina-Gomez G, Vidal-Puig A . Gateway to metabolic syndrome. Nat Med 2005; 11: 602–603.

    CAS  Article  Google Scholar 

  5. 5

    Zhao X, Higashikawa F, Noda M, Kawamura Y, Matoba Y, Kumagai T et al. The obesity and fatty liver are reduced by plant-derived Pediococcus pentosaceus LP28 in high fat diet-induced obese mice. PLOS One 2012; 7: e30696.

    CAS  Article  Google Scholar 

  6. 6

    Rolfe RD . The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130: 396S–402S.

    CAS  Article  Google Scholar 

  7. 7

    Adolfsson O, Meydani SN, Russell RM . Yoghurt and gut function. Am J Clin Nutr 2004; 80: 245–256.

    CAS  Article  Google Scholar 

  8. 8

    Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012; 2012: 902917.

    Article  Google Scholar 

  9. 9

    de Moreno de LeBlanc A, Matar C, Perdigo'n G . The application of probiotics in cancer. Br J Nutr 2007; 98: S105–S110.

    CAS  Article  Google Scholar 

  10. 10

    Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta 2006; 1761: 736–744.

    CAS  Article  Google Scholar 

  11. 11

    Ma X, Hua J, Li Z . Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49: 821–830.

    CAS  Article  Google Scholar 

  12. 12

    Wada T, Noda M, Kashiwabara F, Jeon HJ, Shirakawa A, Yabu H et al. Characterization of four plasmids harboured in a Lactobacillus brevis strain encoding a novel bacteriocin, brevicin 925 A, and construction of a shuttle vector for lactic acid bacteria and Escherichia coli. Microbiology 2009; 155: 1726–1737.

    CAS  Article  Google Scholar 

  13. 13

    Jin H, Higashikawa F, Noda M, Zhao X, Matoba Y, Kumagai T et al. Establishment of an in vitro Peyer's patch cell culture system correlative to in vivo study using intestine and screening of lactic acid bacteria enhancing intestinal immunity. Biol Pharm Bull 2010; 33: 289–293.

    CAS  Article  Google Scholar 

  14. 14

    Higashikawa F, Noda M, Awaya T, Nomura K, Oku H, Sugiyama M . Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial. Nutrition 2010; 26: 367–374.

    CAS  Article  Google Scholar 

  15. 15

    Nomura M, Kobayashi M, Narita T, Kimoto-Nira H, Okamoto T . Phenotypic and molecular characterization of Lactococcus lactis from milk and plants. J Appl Microbiol 2006; 101: 396–405.

    CAS  Article  Google Scholar 

  16. 16

    Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212–228.

    Article  Google Scholar 

  17. 17

    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

    CAS  Article  Google Scholar 

  18. 18

    IBM SPSS Statistics. Available from: accessed on 27 February 2016.

  19. 19

    Li P, Stuart EA, Allison DB . Multiple imputation: a flexible tool for handling missing data. JAMA 2015; 314: 1966–1967.

    CAS  Article  Google Scholar 

  20. 20

    Wang YC, McPherson K, Marsh T, Gortmarker SL, Brown M . Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 818–825.

    Article  Google Scholar 

  21. 21

    Lee JW, Brancati FL, Yeh HC . Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997–2008. Diabetes Care 2011; 34: 353–357.

    Article  Google Scholar 

  22. 22

    Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640–1649.

    Article  Google Scholar 

  23. 23

    Savva SC, Lamnisos D, Kafatos AG . Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes Metab Syndr Obes 2013; 6: 403–419.

    Article  Google Scholar 

  24. 24

    Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659–661.

    CAS  Article  Google Scholar 

  25. 25

    Cao H . Adipocytokines in obesity and metabolic disease. J Endocrinol 2014; 220: T47–T59.

    CAS  Article  Google Scholar 

  26. 26

    Lee S, Kwak HB . Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil 2014; 10: 54–59.

    Article  Google Scholar 

Download references


This study was financially supported by Grants-in-Aid for Scientific Research (Kiban C 23617013 to FH) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. We thank Dr Yongxin Shen at the Clinical Research Center for undertaking the random allocation of study subjects. FH and MS designed the research and had primary responsibility for the final content. FH, MN, TA and ND conducted the research. FH was in charge of statistical analysis and prepared the manuscript. YM and TK supported the statistical analysis of the results from the clinical study. All authors read and approved the final manuscript.

Author information



Corresponding author

Correspondence to M Sugiyama.

Ethics declarations

Competing interests

Hiroshima University has a patent on the use of LP28 as an antiobesity reagent, and FH, MN and MS are co-inventors on that patent. TA, ND, YM and TK declare no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Higashikawa, F., Noda, M., Awaya, T. et al. Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial. Eur J Clin Nutr 70, 582–587 (2016).

Download citation

Further reading